We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




3D Genome Mapping Tool to Improve Diagnosis and Treatment of Genetic Diseases

By LabMedica International staff writers
Posted on 11 Nov 2025

Standard laboratory tests often fail to detect complex DNA rearrangements that underlie many genetic diseases. More...

To bridge this diagnostic gap, researchers have developed a 3D chromosome mapping method that can uncover previously hidden structural variants with remarkable precision.

This breakthrough approach, developed by researchers from the University of Washington School of Medicine (Seattle, WA, USA), could redefine the diagnosis and management of genetic disorders. Unlike traditional one-dimensional DNA sequencing, which reads genetic code linearly, the new technique captures the three-dimensional structure of chromosomes inside the nucleus. This spatial mapping, known as genomic proximity mapping (GPM), is based on Hi-C sequencing and reveals how different regions of DNA physically interact. These interactions can expose deletions, duplications, and rearrangements that remain invisible to conventional sequencing technologies.

In the study published in The Journal of Molecular Diagnostics (Elsevier), the researchers applied GPM to DNA samples from 123 patients with suspected genetic conditions. The method accurately identified all known large chromosomal variants (110 deletions or duplications and 27 rearrangements) with 100% concordance compared to standard tests. Additionally, GPM uncovered 12 novel structural variants that conventional methods had missed, including cryptic rearrangements and complex multi-chromosomal events.

The technology also detected low-level mosaicism, where different cells in a patient carry different genetic changes—an important capability for accurate diagnosis and prognosis. Moreover, GPM requires less DNA than other advanced techniques such as optical genome mapping (OGM) or long-read sequencing (LRS), making it more practical for use on preserved or low-quality tissue samples.

“GPM offers broad clinical benefits. It enables high-resolution, comprehensive genomic characterization, even from compromised samples such as low-quality or archived preserved tissue,” said co-lead investigator Yajuan J. Liu, PhD. “As genomic medicine moves toward precision diagnostics, this new tool addresses current limitations in genetic testing, improving diagnostics and empowering doctors to provide personalized treatment, tailored monitoring, better prognosis, and improved family counseling.”

Related Links:
University of Washington School of Medicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.